Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genomic analysis in lymphoid leukemias.

Sabina Chiaretti1, Jerome Ritz, Robin Foa

  • 1Division of Hematology, Department of Cellular Biotechnologies and Hematology, University La Sapienza, Rome, Italy. chiaretti@bce.uniroma1.it

Reviews in Clinical and Experimental Hematology
|July 20, 2005
PubMed
Summary

Microarray analysis has revolutionized cancer research by identifying gene patterns in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and multiple myeloma (MM). These insights aid in understanding disease variants, patient stratification, and discovering new therapeutic targets.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term stability of posttranscriptional genetic silencing of BCL11A using a shmiR vector in Sickle Cell Disease.

Blood·2026
Same author

Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.

Science translational medicine·2026
Same author

Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

CD19 CAR T-Cell Therapy for Treatment of Chronic Graft-versus-Host Disease.

The New England journal of medicine·2026
Same author

Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.

Nature medicine·2026
Same author

Allogeneic transplant outcomes in T-cell prolymphocytic leukemia: a single-center retrospective study.

Leukemia & lymphoma·2026

Area of Science:

  • Genomics
  • Molecular Biology
  • Cancer Research

Background:

  • Microarray analysis enables the simultaneous investigation of thousands of genes, offering a powerful tool for biological discovery.
  • This technique has yielded significant insights across various cancer types, including hematological malignancies.

Purpose of the Study:

  • To highlight the impact of microarray analysis in understanding gene expression profiles in hematological cancers.
  • To demonstrate the utility of gene expression profiling in identifying disease subtypes, prognostic markers, and therapeutic targets.

Main Methods:

  • Gene expression profiling using microarray technology.
  • Bioinformatic analysis of large-scale gene expression datasets.
  • Correlation of gene expression patterns with clinical and molecular features of cancer.

Related Experiment Videos

Main Results:

  • In acute lymphoblastic leukemia (ALL), microarray studies identified specific gene patterns linked to molecular abnormalities, phenotypes, and prognosis.
  • In chronic lymphocytic leukemia (CLL), gene expression profiling revealed distinct disease variants based on IgVH mutational status and identified similarities with memory B cells.
  • In multiple myeloma (MM), gene expression profiles have enabled patient stratification based on disease aggressiveness and are being used to find prognostic indicators and therapeutic targets.

Conclusions:

  • Microarray analysis is a transformative technology in cancer genomics, providing crucial insights into disease mechanisms and patient outcomes.
  • Gene expression profiling facilitates the identification of novel biomarkers for diagnosis, prognosis, and therapeutic intervention in hematological malignancies.
  • Continued application of microarray technology holds promise for advancing personalized medicine in oncology.